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Catheter ablation is an established tool for the treatment of
patients with atrial ﬁbrillation (AF),1 and pulmonary vein
isolation (PVI) has been a cornerstone strategy for percuta-
neous management of paroxysmal AF.1,2 Unfortunately,
long-term success has been constrained by the time-
consuming and unpredictable nature of point-by-point focal
ablation and the technical limitations on the effectiveness of
ablation lesions to create a durable PVI. These procedural
complexities have been historically notable with nonirrigated
radiofrequency (RF) catheters and are only marginally
improved with external irrigation.Although focal RF catheters have been the standard of
care for AF ablation,1 balloon-based technologies were
developed in an attempt to deliver ablative energy in a more
continuous pattern without conduction gaps during cardiac
tissue isolation.3,4 Since the release in 2010 of the ﬁrst-
generation cryoballoon (CB1; Arctic FrontTM, Medtronic
Inc, Minneapolis, MN) in the United States, data from both
single-center studies and multicenter registries have demon-
strated acute PVI and freedom from AF at rates comparable
to those of RF.1,5,6
The cryoballoon ablates with minimal disruption of the
endothelium, creates relatively discrete lesions, and pre-
serves myocardial architecture, followed by replacement
with ﬁbrous tissue through the Joule–Thomson effect.7 The
basic biophysical steps that result in cell death include the
formation of intracellular and extracellular ice crystals,
which causes withdrawal of intracellular water. Additional
cell death results from the consequences of cell thawing, withhttp://dx.doi.org/10.1016/j.hrthm.2015.03.021.
Figure 1 Right anterior oblique (RAO) view of right inferior pulmonary
vein cryoballoon engagement angle when transseptal site is lower and more
anterior. Example of patient with atrial septal occlusion device at the
secundum defect location better demonstrates the transseptal location.
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rupture.
The second-generation cryoballoon (CB2; Arctic Front
AdvanceTM, Medtronic) was released in 2012. It was
designed to achieve more uniform cooling across the entire
distal hemisphere of the balloon using 8 injection tubes vs
the original 4-port design of the CB1.8,9 Acutely, the time to
achieve PVI has been shortened and acute PV reconnection
is rare; chronically, freedom from AF seems to be higher in
nonrandomized studies.10–18 Also, the rates of PV recon-
nection in patients with recurrent AF are remarkably low
compared with historic controls.19
Although research has indicated consistent patient out-
comes with CB2, a comprehensive report of CB2 procedural
recommendations has not been published. In an effort to
drive consistent outcomes and minimize complications, this
report reviews the current best practices from a group of
experienced centers to create a user’s consensus guide for
cryoballoon ablation.Best practices: The cryoballoon ablation
procedure
Femoral and left atrial access
The current FlexCathTM (Medtronic) sheath for delivery of
CB2 has an outer size of 15Fr; therefore, we recommend
initial femoral vein access with a shallow angle of entry and
then predilation with a 14Fr short dilator. The FlexCath can
be exchanged over a long stiff guidewire using a corkscrew
motion or rotation for initial engagement. Full anticoagula-
tion with IV heparin bolus should be given before initial
transseptal access, because unacceptable incidences of
thrombus formation have been observed via intracardiac
echocardiography (ICE) shortly after any sheath placement
in the left atrium (LA) even if heparin was given immediately
after transseptal access. A target activated clotting time
between 350 and 400 seconds is recommended. Patients
who already are taking warfarin typically continue on a
therapeutic international normalized ratio level. However,
the management of patients taking novel oral anticoagulants
varies, and most agree that until reversal agents are available,
12 to 24 hours of freedom from novel oral anticoagulants
should be obtained. In general, anticoagulation management
should not be different than prior AF ablation practices.
Initial LA access is best achieved using a standard
transseptal sheath (both Mullins and SL-1 curve have been
used) that is then exchanged for a FlexCath steerable sheath
over a long stiff wire. We recommend a low anterior
transseptal puncture that is near or on the limbus of the
septum to allow more space for the balloon to be rotated
posteriorly to the right inferior PV as well as mechanical
advantages while accessing the other PVs (Figure 1). With-
out sufﬁcient distance between the puncture site and the right
inferior PV, optimal balloon positioning and occlusion may
be difﬁcult. Also, a low puncture location improves balloon
contact with the inferior aspects of the PVs. We highly
recommended using ICE to improve the safety of transseptalcatheterization. ICE will also provide early detection of
complications (eg, catheter-related thrombus and pericardial)
in ablation cases. The location of the transseptal access is
best at the lower third of the septum and anterior reach at the
plane of ICE where the mitral valve is in view (Figure 2).
Bending of the distal 15-cm portion of the typical transseptal
needle can improve transseptal needle engagement with the
anterior portion of the septum.20
While monitoring with ICE and maintaining a steady
manual pressure, a simple “clockwise” and “counterclock-
wise” movement of the handle can ease the sheath across the
septum. Slowly remove the dilator and exchange it for a
guidewire. Occasional difﬁculties may be encountered
pushing the FlexCath sheath across the septum, especially
at the transition of the dilator to the sheath. Some have found
that placing the stiff exchange guidewire in the left superior
PV or maneuvering the guidewire to the right superior PV
will allow an easier push from the inferior vena cava directly
across the septum and up toward the right superior PV in a
straighter manner, thereby overcoming the tougher septal
transition. Next, aspirate (by syringe) approximately 15–20
mL to remove any possible air in the sheath while tapping the
handle to release trapped air. Flush and connect the sheath to
a low-ﬂow drip saline bag (1–3 mL/min).
After preparing the balloon and balloon sleeve in hepari-
nized saline, insert the cryoballoon into the sheath using the
protective sleeve. Slowly advance the cryoballoon catheter
over the entire length of the sheath. Advance the AchieveTM
(Medtronic) mapping catheter using the cryoballoon shaft
markers to conﬁrm appropriate positioning. The mapping
catheter should always lead the cryoballoon catheter to
prevent trauma from the stiffer cryoballoon catheter tip.
Fluoroscopy can be minimized by using markers on the
cryoballoon body. When the ﬁrst white band is at the valve
of the sheath, the balloon is at the distal tip of the sheath. The
second white band indicates the cryoballoon is out of the
sheath and is ready for full inﬂation.
Figure 2 A: Intracardiac echocardiography (ICE) demonstrating lower and more anterior transseptal access (arrow). LA¼ left atrium; MV¼mitral valve; RA
¼ right atrium. Shown is transseptal sheath through the inferior septum location with thicker inferior limbus as well as anterior position with MV seen on ICE. B:
Anatomic layout of optimal transseptal site (white oval). (Image modiﬁed courtesy of Visible Heart Lab, University of Minnesota. See Online Supplementary
video.)
Heart Rhythm, Vol 12, No 7, July 20151660Positioning and occluding the vein
We describe 6 simple but critical maneuvers that can be used
to improve outcomes, reduce complications, ensure circum-
ferential lesion creation, and create substantial antral LA
substrate modiﬁcation. An antral level of isolation contributes
to the success of cryoballoon PVI, and it may reduce
complications by maximizing the distance between the balloon
and collateral structures beyond the LA chamber. The 6 critical
maneuvers are given in chronological order, as follows.1. When maneuvering the sheath to the desired PV, always
lead the balloon with the soft-tipped mapping catheter to
avoid sheath trauma in the LA or PV. Contrary to the
focal RF catheter technique in which the majority of
catheter maneuvering occurs at the ablation handle, the
majority of cryoballoon positioning is dependent on the
sheath and maintenance of forward pressure on the
balloon shaft. Because the cryoballoon sheath is stiff,
there is a predictable 1:1 transference of movement force.
Thus, the cryoballoon tool sets are easier to master and
require shorter “learning” periods.2. Distal positioning of the Achieve (in the PV) will
facilitate advancement of the balloon to the respective
PV. We recommend using the lower PV branch for
isolation of inferior veins to provide the best angle for
balloon engagement of the lower portion of the PV
ostium, which frequently is the worst area of balloon-to-
PV contact. Navigation of the Achieve into each of the
PVs is best facilitated with the use of ICE, which can
reduce the need for ﬂuoroscopy. The PVs, FlexCath, and
Achieve are easily visualized with ICE.3. Advance the balloon outside the sheath toward the PV
ostium while taking precautions not to deep-seat the
balloon. The sheath should be aligned with the angle of
the targeted PV. Because balloon inﬂation occurs usinglow pressure, it is unlikely to cause mechanical trauma to
the PV; however, inadvertent inﬂation inside the PV
should still be avoided.4. The Achieve can provide additional support for the
cryoballoon, but the majority of the control of balloon–
PV engagement is via the deﬂectable FlexCath sheath,
which should be used to provide the primary support
during PV occlusion. The sheath can be advanced against the
proximal hemisphere of the balloon during cryoablation for
both support and catheter advancement for better occlusion.
Achieve positioning relative to the balloon is not critically
important as long as balloon-to-PV antrum is maximized.5. PVI is best achieved by application of forward pressure to
ensure the optimal balloon-to-PV ostium contact, which
will result in successful isolation of the respective vein.
With full occlusion of the PV, a 1- to 2-mL initial
injection of radiopaque contrast will provide venographic
evidence of balloon occlusion or leak detection.
A. If the venogram does not reveal a leak at the ostium,
do not immediately ablate. If no leak is visible on
venogram, withdraw the cryoballoon slightly and
allow a leak around the PV–balloon interface to better
deﬁne the PV ostium and ensure a proximal ablation.
In some cases, this technique will reveal that the
balloon was inside the PV and not at the PV ostium.
Reapply only the minimal amount of pressure needed
to regain occlusion before ablation. This technique is
often denoted as the “proximal-seal” technique. Abla-
tion can also be initiated before advancing the balloon
to increase the balloon pressure and assist in keeping
the balloon more proximal antrum, thereby achieving
a lesion set with closer resemblance to the typical wide
area circumferential ablation. This technique also
lessens the risk for phrenic nerve injury (PNI) at the
right superior PV (Figure 3).
Figure 3 Proximal seal technique. Instead of initiating ablation after initial venogram, CB is ﬁrst gently pulled back to reveal the real pulmonary vein (PV)
ostium by noting contrast leak. The true antrum is much further back than initially realized. CB at left superior PV (A) and venogram (B) showing CB pulled back
to reveal the real PV ostium (see Online Supplementary video).
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additional pressure toward the side of the leak will
often secure occlusion at an optimal location. If
complete occlusion cannot be made, then the PV
antrum cross-section is likely more ovoid. In this case,
separate application of ablation from a different angle
should be performed, keeping in mind the area of best
contact and that the summation of the contact should
surround the PV antrum. Color ﬂow Doppler imaging
to search for leak and poor contact may be used in
place of contrast injection with a sweep of the array
across the balloon. Using ICE in Doppler mode
imaging is particularly important in patients with renal
insufﬁciency or a history of contrast agent intolerance/
allergic reaction(s).6. With the best-ﬁt occlusion, the Achieve mapping
catheter should be used to obtain PV potential record-
ings for real-time monitoring before initiation of the
ablation. Torque can be applied to the Achieve mapping
catheter to prolapse the circular mapping poles toward
the antrum to be able to record approximately more than
90% of all PV potentials to assess the time to isolation
(TTI). Optimal Achieve position is demonstrated in
Figures 1 and 3. One of the most critical indicators and
predictors of permanent PVI is the TTI (best if o90
seconds). Reduction of the ablation time is also consid-
ered when a short TTI is seen (o30 seconds) by
reducing the total ablation time to 150 seconds. If
desired, exit block from the PV can also be established
during the ablation by pacing from the Achieve. Rarely
is the Achieve required to provide distal cryoballoon
anchoring for optimal positioning as a tradeoff for the
inability to record the proximal PV electrogram. Most of
the support for the balloon should be provided by the
FlexCath sheath. In this setting, PV recording on the
Achieve can be re-established after initiation of a
freezing cycle within approximately 10 seconds, with
a pullback on the Achieve until the PV electrogram can
be seen. After approximately 15 seconds into the
freezing cycle, the central lumen is frozen, and the wire
cannot be moved.PV antrum ablation
Once the balloon is in the correct position at the PV antrum,
the ablation process is initiated at the CryoConsole (Med-
tronic) interface. Although a single operator technique is
possible, a dual-operator method is more common whereby
the second operator is typically a nursing staff member who
will assist in operations more distal to the cryoballoon
catheter, including CryoConsole operation. The following
5 steps highlight the procedural period that is encompassed
during the cryoballoon ablation.1. Before ablation, prepare a small 1-mL injection of
contrast to ensure continued occlusion after freeze ini-
tiation. In some cases, the onset of freezing and balloon
compliance change can dislodge the balloon and create a
leak. We recommend a 180-second initial ablation with
CB2, at a minimal temperature no colder than –551C.2. Avoid maneuvering the cryoballoon after initiation of
ablation. A “post-cryo initiation” maneuver may increase
the risk of mechanical trauma and provide a false sense of
durable ablation. Within the ﬁrst 15 seconds of ablation, a
layer of ice can be observed on the surface of the balloon,
which will act as a thermobarrier and decrease energy
transfer to the tissue. The acute block that may be
observed before initiating a pulldown technique is tran-
sient. If a lower-positioned seal is challenging, it is better
to improve the ablation by ablating the upper portion of
the PV ostium and then the lower portion of the PV
ostium in 2 full separate applications. This situation
occurs frequently because the majority of PV antrum
cross-sections are ovoid.3. After freeze application, allow the balloon and tissue
interface to thaw. The postablation thawing process can
be slow. Do not move the balloon catheter until the
catheter temperature reading reaches 35ºC (even though
the balloon automatically deﬂates at 20ºC). The balloon
may remain attached to tissue after balloon deﬂation in a
phenomenon known as “late adhesion,” and mechanical
manipulation might result in tissue damage or even
perforation.
Figure 4 Intracardiac ultrasound image of CB at left inferior pulmonary
vein (PV) and color Doppler revealing ﬂow from left superior PV. CB
outside of the PV antrum forms the “golf ball on tee” image (see Online
Supplementary video).
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balloon to enlarge and stiffen, then engage the PV ostium.
The ostium should be fully engaged on the second
ablation. This maneuver can help expand the antral
location of the intended lesion and can be conﬁrmed on
ICE with the equator of the balloon outside of the vein
yielding the “golf ball on a tee” appearance (Figure 4).5. To enhance the timesaving advantage of cryoballoon
ablation, parallel processing and planning can be per-
formed during the freeze cycle. Review the venogram of
the current ablation to assess contact and determine if
another ablation at a different angle is needed. The
operator can also review the PV venogram and plan the
next ablation site, balloon angle, or target branches for
placement of the Achieve catheter. Also, while ablating
the left-sided PV, the operator can identify an optimal
pacing location for the right phrenic nerve (PN). This will
save procedure time when transitioning from left- to right-
sided PV.
Cryoballoon dosing and temperature
Various dosing regimens exist with recommendations from 2
to 5 minutes per freeze. Historically, 4 minutes was the
standard for CB1 based on procedures in the STOP AF
clinical trial protocol.5 Since the release of CB2, shorter
application times have been explored as a strategy to avoid
collateral tissue injury without compromising efﬁcacy. For
example, a recent investigation by Ciconte et al18 demon-
strated an 80% freedom from AF in 143 consecutively
enrolled subjects treated with a single 3 minute freeze
using CB2.
The operator must understand the physiology of cryoe-
nergy transfer in order to understand dosing. In brief,
cryoballoon energy transfer is dependent on the source of
cryoenergy, balloon–tissue contact area, collateral warming,
and time. The 2 most important operator-controlled factors
are time and balloon–tissue contact. These 2 factors (along
with nadir temperature) have a direct impact on lesion depthin an exponentially decrementing manner. Simply, longer
ablation time will correlate to a deeper lesion; however, the
ﬁnal ablation time is shortened when considering the balance
of safety and collateral tissue freezing. Lastly, this longer
ablation time to deeper lesion correlation is not completely
linear. There is a penultimate depth of lesion penetration
(regardless of time) that is established by the limitation of
heat dissipation over space.
Although the operator does not directly control nadir
temperature, it is important for operators to understand and
monitor temperature during the procedure. Importantly, the
operator does determine when to terminate a freeze. The
temperature displayed on the CryoConsole is not tissue
temperature; instead it is a return gas temperature measure-
ment. The balloon–tissue interphase temperature is typically
–70 to –80ºC, but the temperature on the CryoConsole is the
return gas temperature, and it often ranges between –40 to
–50ºC for optimal lesions. Therefore, the only conclusion
that can be made from the return gas temperature is that if the
temperature is cold (eg, below –40ºC), it likely reﬂects good
tissue ablation. A steep and rapid descent in temperature
(colder than –40ºC at 30 seconds) and nadir temperatures of
–55 to –60ºC are potential indicators of a distal cryoballoon
location (rather than an antral position). We recommend that
the ablation be terminated in either scenario and cryoballoon
positioning conﬁrmed.
The most important physiologic end-point to predict
successful PVI is TTI as identiﬁed by the Achieve catheter,
as this is the only true tissue physiology that can be
monitored. PV potentials should be closely monitored at
the initiation of the freezing cycle, during the freeze, and
after the ablation is complete. Although data are needed to
clearly correlate long-term outcomes with abbreviated freeze
protocols, our experience supports a more conservative
dosing time of 150 seconds if TTI is achieved at 30 seconds
or less. If the PV is not isolated within 180 seconds, we
recommend against increasing time or advancing the cry-
oballoon deeper into the PV. Rather, the operator should
modify the cryoballoon–tissue contact.
To allow deep tissue warming, maximize cryoablation
efﬁciency, and reduce the risk of collateral damage, we
recommend against an immediate follow-up application if
the cryoballoon nadir ablation temperate reaches below –
55ºC. This tissue rewarming time may potentially reduce
the risk of PNI or esophageal injury. If desired, ablation
can be performed at another target PV while allowing
warming.
With regard to dosing, esophageal temperature mon-
itoring (discussed later) also may be helpful. For example,
application of a 180-second ﬁrst lesion is rarely associated
with an esophageal temperature below 25ºC. Reducing
application duration during a repeat freeze to 150 seconds
or less may be warranted because of the faster temperature
decline on the repeat freeze thus avoiding deeper tissue
injury. Repeated ablations for more than 2 times at a
similar location should be avoided to prevent collateral
injury.
Figure 5 Recordings of the diaphragmatic compound motor action potential (CMAP) during pacing from the coronary sinus (CS) catheter at 60 bpm located
in the superior vena cava and during application of cryoenergy to the right superior pulmonary vein. CMAP amplitude (asterisk) signiﬁcantly decreased at 180
seconds of cryoballoon application. Note that the pulmonary vein is isolated. At the time of phrenic nerve palsy, CMAP amplitude is a fraction of baseline CMAP
amplitude. CMAP amplitude increased after cryoenergy was discontinued but did not return to its original value. A decrease in CMAP amplitude by 35% from
baseline predicted and prevented phrenic nerve injury. (Reproduced from Lakhani M, Saiful F, Parikh V, Goyal N, Bekheit S, Kowalski M. Recordings of
diaphragmatic electromyograms during cryoballoon ablation for atrial ﬁbrillation accurately predict phrenic nerve injury. Heart Rhythm 2014;11:369–374.)
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As demonstrated in recently published studies, the improved
cooling characteristics of CB2 translate into improved acute and
long-term efﬁcacy.10–18 However, enhanced cooling character-
istics may also result in a greater potential for collateral damage
to noncardiac structures such as the PN and the esophagus. We
recommend closely monitoring temperature, application dura-
tion, contact force, anesthesia, TTI, type of esophageal tissue,
and distances between the catheter and collateral structures (PN,
lungs, esophagus). Following we discuss techniques to avoid
PNI and esophageal damage.Prevention of PNI
Right PN palsy is the most common complication associated
with cryoballoon ablation; persistent PNI lasting after the
procedure has been reported as high as 8.3%.1,5 Our experience
suggests that the risk for persistent PNI can be minimized by
ensuring the cryoballoon position is as antral as possible as
described in the ablation section. Most important are active
monitoring of the PN during ablation and terminating ablation
immediately at the ﬁrst sign of hypothermic effect. To pace and
monitor PNI, paralytics should not be administered during
cryoablation. If paralytics were administered during the induc-
tion of general anesthesia, sufﬁcient time should be allowed for
the paralytic effect to reverse before ablation, or neostigmine
may be used as a reversal agent.
To monitor PN function, the nerve should be paced at
twice the capture threshold using a deﬂectable catheter. Werecommend placing the pacing catheter in the superior vena
cava (SVC) and above the level of the ablation. A consistent
site for PN capture is near the junction of the SVC and the
right subclavian vein or the anterolateral portion of the SVC,
near the atrial–SVC junction.
Palpation of the strength of diaphragmatic excursion
during PN pacing, below the costal margin, is the most
common method of monitoring PN function. In addition to
palpation, monitoring of the diaphragmatic compound
motor action potential (CMAP) can increase the sensitivity
of PNI early detection (Figure 5).21 Combining CMAP and
palpation has decreased the incidence of PNI to less than
1.5%.22 Several other methods proposed for monitoring
PN in conjunction with CMAP and palpation are ICE,23
fetal heart monitoring,24 and external thoracic pressure
monitoring (Table 1).25 A detailed review of all the
methods for monitoring of PN were reported by Kowalski
et al.24 The ICE catheter can also provide conﬁrmation of
correct positioning of the balloon by visualizing the main
portion of the balloon outside of the vein, thus reducing the
risk of freezing deeply in the vein and the risk of PNI
(Figure 4).
Once PNI occurs, the operator should immediately stop
ablation by “double stop” technique or immediate balloon
deﬂation. Ghosh et al26 concluded that rapid balloon
deﬂation results in more rapid tissue rewarming, leading to
prevention of persistent PNI with no adverse events.
Continued pacing of the PN could assist in evaluating the
time for recovery of function. If the duration of recovery is
Table 1 Comparison of different strategies for monitoring phrenic nerve palsy during cryoballoon ablation: Pros and cons of various PN
monitoring strategies
Method Description Advantages Disadvantages
Fluoroscopy Direct visualization of diaphragmatic motion Sensitive method for monitoring
diaphragmatic motion
Additional radiation exposure to
patient and operator
Does not predict PN injury
Palpation Palpation of diaphragmatic excursion Reliable and practical method for
monitoring diaphragmatic
motion
Requires additional staff member
Palpable strength of
diaphragmatic excursion may
vary with respiration
Electromyography Recording of diaphragmatic CMAP by 2
standard surface electrodes positioned
across the diaphragm or by advancing a
quadripolar catheter in the right hepatic
vein during PN pacing
Earliest detection of PN injury CMAP signals might be susceptible
to respiratory variationsSimple, reliable, and easily
applicable Baseline amplitude must be
adequateOnly technique that predicts PN
injury Affected by paralytic agents
Auditory
cardiotocography
Decrescendo pitch on fetal heart monitor
(placed across patient’s chest; can detect
diaphragmatic contractions)
Auditory cue to the operator Difﬁcult to record in obese
patientsMay portend PN injury before
palsy
Intracardiac
echocardiography
Direct visualization of diaphragmatic
excursion
Minimal radiation exposure to
patient and operator
Requires additional venous access
and intracardiac ultrasound
CMAP ¼ compound motor action potential; PN ¼ phrenic nerve.
Modiﬁed with permission from Kowalski M. Prevention of phrenic nerve palsy during cryoballoon ablation for atrial ﬁbrillation. In: Chan N-Y, editor. The
Practice of Catheter Cryoablation for Cardiac Arrhythmias. Hoboken, NJ: Wiley Blackwell; 2014:67–81.
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different PV branch and with a more antral position of the
balloon. If palsy persists after the procedure, an inhalation–
exhalation chest X-ray ﬁlm is recommended to establish a
baseline for PNI for comparison to recovery assessment at a
later time. Intravenous steroids may be administered to
decrease inﬂammation.Prevention of esophageal injury
Esophageal injury is a complication observed in both RF and
cryoablation procedures. It is a direct result of the proximity
of the esophagus and the posterior wall of the LA. The
severity of the injury can vary, manifesting as esophageal
erythema, esophageal ulcer/lesion, or atrioesophageal (AE)
ﬁstula. Recent research has demonstrated CB2 esophageal
lesion rates of 3.2% to 19% as observed through postproce-
dural endoscopies, with the lowest rates (3.2%) reported
when a luminal esophageal temperature (LET) cutoff of 121–
151C is used.27–31 When LET and other measures are used,
damage can be limited to esophageal lesions, which fre-
quently heal in a few weeks. If unmonitored, esophageal
damage may result in rare and generally fatal AE ﬁstulas. The
reported rate of AE ﬁstula with CB1 and CB2 is approximately
1 in 10,000, whereas the incidence of AE ﬁstula with RF varies
between 0.1% (1:1000) and 0.25% (1:400).1,32 Even though
the root cause has not been determined, caution should be used
when treatment time exceeds 4 minutes, more than 2 freezes
are applied to a PV, and balloon nadir temperatures exceed –
60ºC.
The impact of CB2 ablation on esophageal thermal injury
was recently investigated by 2 different groups.28,29 Freezecycles of 240 seconds were followed by a safety freeze cycle of
another 240 seconds. Whereas Metzner et al28 did not have a
predeﬁned temperature cutoff, Fürnkranz et al29 stopped the
freeze cycles at an esophageal endoluminal temperature of
o51C. The lowest temperature in the esophagus and the lowest
temperature in the CBwere noted. Postablation, all patients were
treated with pantoprazole 40 mg daily for 6 weeks, and an
endoscopywas performed at 2 days postablation.Metzner et al28
demonstrated a 12% incidence (6/50 patients) of esophageal
thermal injury, whereas Fürnkranz et al29 reported an incidence
of 19% (6/32 patients). Compared to esophageal thermal lesions
after RF-based ablation, lesions after CB ablation tended to be
more superﬁcial; most patients were completely asymptomatic
and all lesions were resolved during repeat endoscopies.
Importantly, none of the patients developed an atrial-to-
esophageal ﬁstula.
Based on their statistical analysis of correlating the lowest
esophageal temperature and the endoscopic ﬁndings, Metz-
ner et al28 recommend an esophageal temperature cutoff of
101C (sensitivity 100%, speciﬁcity 93%), whereas Fürnk-
ranz et al29 suggest a cutoff of 121C (sensitivity 100%,
speciﬁcity 92%) for causing esophageal ﬁstula injury.
Although this research brings us closer to better under-
standing techniques to prevent esophageal injury, it is
important to understand that no direct correlation has been
made between esophageal ﬁstula formation and temperature.
Other predisposing factors may be more important than
temperature alone. The suggested endoluminal esophageal
temperature cutoff values need to be evaluated prospectively
in future studies; however, consideration of the currently
recommended minimal esophageal temperatures may con-
tribute to safer use of CB2.
1665Su et al Best Practice Guide for Cryoballoon AblationIn the interim, as outlined in the 2012 HRS/EHRA/ECAS
expert consensus statement, the authors reinforce luminal
esophageal temperature monitoring, a barium swallow to
outline the esophagus, duration of energy application,
prescription of proton pump inhibitors, and reduced contact
force as options to minimize esophageal injury.1
Postablation care
Immediate postablation testing should be similar to that for
other AF ablation methods; however, our experience to date
indicates that adenosine for assessment of PV connection
recovery has been of limited use and rarely positive.
Postprocedural groin management also is not different than
that for traditional RF ablation. An increased rate of groin
access complication due to larger sheath size has not been
reported. Postablation anticoagulation duration, given the
lesser endocardium injury with cryoablation, is considered to
be adequate at 1 month’s time; this duration correlates with
the complete tissue healing time observed in animal and
in vivo experiences.
Outcomes
Cryoablation is a safe and effective tool for the treatment of
paroxysmal AF with a high rate of durable procedural PVI19
and long-term freedom from AF.10–18 Eight single-center
studies on CB2 have demonstrated a single procedure, off
antiarrhythmic drug, freedom from AF Z80%.10–18 In
contrast, freedom from paroxysmal AF in recent, large RF
multicenter studies and surveys (since 2010), including
clinical study results from recent RF technology advance-
ments, has been reported to be 61%–74%.1,33 In addition, RF
catheter studies evaluating PVI durability at remapping
procedures have reported between 23% and 35% of patients
had complete PVI at 3 months and only 8% of patients at 12
months.1 The safety proﬁle for the 2 therapies is similar. In a
large multicenter registry (German Ablation Registry), the
overall rate of major complications were similar for cryoa-
blation (CB1) and RF (4.6% for both groups), with PN palsy
constituting nearly half of cryocomplications (2.1%).6
Conclusion
Cryoballoon ablation of AF is a useful tool for PVI and antral
modiﬁcation. The speciﬁc technical recommendations dis-
cussed here in detail will make the cryoballoon procedure a
safer and more effective tool for treatment of AF.
Appendix
Supplementary data
Supplementary material cited in this article is available
online at http://dx.doi.org/10.1016/j.hrthm.2015.03.021.
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